Clinical Trials Sponsored by Meo coffee

Total 869 results

LEO Pharma

Completed

A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities

Actinic Keratosis

Italy
LEO Pharma

Completed

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

Atopic Dermatitis

United States, France, Netherlands
LEO Pharma

Completed

Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds

Psoriasis Vulgaris

United States, United Kingdom, Canada, Germany
LEO Pharma

Terminated

A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis (APPLES)

Atopic Dermatitis

United States, Netherlands, United Kingdom, France, Canada, Ireland, Austria, Germany, Poland
LEO Pharma

Completed

Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks

Actinic Keratosis

Germany
LEO Pharma

Completed

The Real Life Topical Field Treatment of Actinic Keratosis Study (RAPID-ACT)

Actinic Keratosis

Netherlands
LEO Pharma

Completed

Efficacy and Tolerability of Enstilar® in Daily Practice

Plaque Psoriasis

Germany
LEO Pharma

Completed

LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients

Secondary Hyperparathyroidism

Germany, Poland
LEO Pharma

Withdrawn

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single and Multiple Doses of LEO 142397 in Healthy People, Including Japanese

Healthy

United Kingdom
LEO Pharma

Withdrawn

Investigation of Flare and Remission in Subjects With Atopic Dermatitis

Atopic Dermatitis

Netherlands
LEO Pharma

Terminated

Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beisong®) Cream and Fucicort® Lipid Cream Vehicle in Clinically Infected Atopic Dermatitis/Eczema

Infected Atopic Dermatitis/Eczema

China
LEO Pharma

Completed

LEO 124249 Ointment in the Treatment of Alopecia Areata

Alopecia Areata

United States
LEO Pharma

Completed

A Vasoconstriction Study With LEO 90100

Psoriasis Vulgaris

France
LEO Pharma

Completed

Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100

Psoriasis Vulgaris

France
LEO Pharma

Completed

Innohep® in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis

Deep Vein Thrombosis

Bulgaria, Croatia, Czechia, France, Germany, Poland, Romania, Serbia, Spain
LEO Pharma

Completed

Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne

Acne Vulgaris

United States
LEO Pharma

Completed

A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis

Actinic Keratosis

Canada, United States
LEO Pharma

Completed

The Use of Picato® (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice (PrAKtice)

Actinic Keratosis

Greece
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Actinic Keratosis

United States
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up

Actinic Keratosis

United States
LEO Pharma

Completed

Trial Twice Daily Application of LEO 124249 Ointment 30 mg/g in Treatment of Mild to Moderate Inverse Psoriasis

Inverse Psoriasis

Germany
LEO Pharma

Completed

An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects

Psoriasis Vulgaris

United States, Canada, United Kingdom, Germany, Romania, France, Poland
LEO Pharma

Completed

Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation

Plaque Psoriasis | Psoriasis Vulgaris

Germany
LEO Pharma

Completed

Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)

Secondarily Infected Traumatic Lesions | Impetigo

United States, South Africa
LEO Pharma

Completed

Dermatopharmacokinetic Trial of LEO 90100 Foam

Healthy

Japan
LEO Pharma

Terminated

Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.

Alopecia Areata

Denmark
LEO Pharma

Completed

An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life

Psoriasis Vulgaris

United States
LEO Pharma

Completed

Skin IaM: An Exploratory Clinical Trial to Evaluate Changes in Skin Appearance, Colour, and/or Texture Following the Induction of a Local Inflammatory Skin Response

Skin Inflammation

Australia
LEO Pharma

Completed

Vasoconstriction Trial With LEO 90100 Aerosol Foam

Psoriasis Vulgaris

France
LEO Pharma

Completed

Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts

Anogenital Warts

Denmark
LEO Pharma

Completed

LEO 32731 - A Phase I Study in Healthy Subjects

Psoriasis Vulgaris

United Kingdom
LEO Pharma

Completed

Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
LEO Pharma

Completed

LP0058-1005 - A Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy Subjects

Psoriasis Vulgaris

United Kingdom
LEO Pharma

Completed

Skin Irritation Test of LEO 80185 Gel in Healthy Japanese Subjects

Skin and Connective Tissue Diseases

Japan
LEO Pharma

Completed

Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

Scalp Psoriasis

United States
LEO Pharma

Completed

The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris

Psoriasis Vulgaris

Japan
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Gel in the Treatment of Scalp Psoriasis

Psoriasis of Scalp

Canada, Denmark, France, Norway, Portugal, Spain, Sweden, United Kingdom
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris

Psoriasis Vulgaris

Belgium, Canada, France, Germany, Netherlands, Spain, United Kingdom
LEO Pharma

Completed

Efficacy of Calcipotriol Plus Betamethasone Gel Versus Calcipotriol Scalp Solution in Scalp Psoriasis

Psoriasis of Scalp

France, Canada, Belgium, Denmark, Sweden
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris

Psoriasis Vulgaris

Ireland, Germany, United Kingdom, Canada, Sweden
LEO Pharma

Completed

Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis

Psoriasis

United States
LEO Pharma

Completed

Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel)

Scalp Psoriasis

Germany
LEO Pharma

Completed

The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847

Renal Impairment

Canada
LEO Pharma

Completed

LEO 22811 - Single Dose Bioavailability Study of Tablet Versus Oral Solution in Healthy Subjects

Healthy

United Kingdom
LEO Pharma

Completed

Assessment of the Phototoxic Potential of LEO 29102 Cream

Atopic Dermatitis

France
LEO Pharma

Completed

A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis

Atopic Dermatitis

Netherlands
LEO Pharma

Terminated

Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis.

Atopic Dermatitis

Germany
LEO Pharma

Terminated

Cromoglicate in Mastocytosis

Mastocytosis

Germany
PD Dr. med. Volker Heinemann
MGO Ruhr-University Bochum (RUB)

Recruiting

Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model (2016-003295-46)

Colo-rectal Cancer | RAS Wild-type | UICC III | UICC II + RF | UICC IV Curative Intent

Germany

3

Subscribe